Sentence examples for binding to human breast from inspiring English sources
In addition, the pIX-pK displayed on the Ad capsid could mediate HSPGs dependent binding to human breast cancer cells (AU-565).
HCAb2 showed punctate membrane staining on MDA-MB-231 cells and preferential binding to human breast tumor tissues in comparison to normal breast tissues.
To determine if HCAb2 reveals selective binding to human breast tumors, a cohort of fresh frozen human breast tissue samples was screened with HCAb2.
Concerning breast cancer, Reubi et al. (2017) demonstrated that binding of 125I DOTA-JR11 to human breast cancer tissue was much higher than that of 125I DOTA-Tyr3-octreotide 125I DOTA-Tyr3-octreotide 125I DOTA-Tyr3-octreotideJR11 vs 111In-DOTA-Tyr3-octreotate to 40 human breast cancer tissue samples (Dalm et al., 2017).
In sharp contrast, neither GAL4 protein nor mouse non-specific IgG showed such binding activity, indicating that TfRscFv-GAL4 fusion protein binding to human gastric cancer cells and human breast cancer cells is through the TfRscFv domain but not GAL4 protein domain.
In this regard, while VVA targets mostly O-linked carbohydrates, binding of GS-I lectin to human breast carcinomas may be related to other unknown antigens.
The optimized Fc domain shows increased binding to human C1q.
Multiple factors, known and unknown, contribute to human breast cancer.
ABCC10 expression was correlated to human breast cancer subtype using breast tissue microarrays.
Direct (saturation) radioligand binding to SKBR-3 human breast cancer cells of (a) 111In-DOTA-trastuzumab Fab or (b) 64Cu-DOTA-trastuzumab Fab, in the absence (total binding; TB) or presence (non-specific binding; NSB) of excess (16 μM) unlabeled trastuzumab IgG.
Thus, there was a need to optimize G3 by assessing the effects of histidine-based tags on the biodistribution of G3 in normal tissue.> A competition assay showed that the His6-G3 labelled with cold indium and cold iodine, (HE 3-G3 and untagged G3 all competed with [99mTc(CO)3]+-G3 DARPin-His6 for binding to HER2-positive human breast cancer cells (BT474).
